Actively Recruiting
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
Led by IRCCS San Raffaele · Updated on 2025-01-23
2000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are developing an artificial intelligence tool to predict how patients with metastatic non-small cell lung cancer (NSCLC) will respond to treatments. This study focuses on patients treated with either immunotherapy alone or chemo-immunotherapy combinations as first-line treatment. The goal is to identify patients who may not respond well, experience severe toxicities, or survive longer than average, to help personalize their care and follow-up plans. The study observes two groups of patients: those receiving immunotherapy alone and those receiving chemo-immunotherapy. Data will be collected both retrospectively and prospectively from clinical, laboratory, radiological, and pathological sources at specific timepoints. This information will be analyzed to build and continuously update a predictive score that weighs the importance of various factors over time. Participants will have their disease progression, immune-related lung toxicity, and survival monitored over time. Early disease progression will be assessed within 8 to 12 weeks after treatment start, lung toxicity will be tracked up to 96 months, and survival outcomes will be evaluated at a 3-year mark. The study aims to use this data to improve individual patient management and treatment decisions.
CONDITIONS
Brief Title
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histological or cytological diagnosis of NSCLC
- Stage IV according to investigator's staging procedures or locally advanced tumour not suitable for radical treatment
- Treatment with at least 1 cycle of mono-immunotherapy or chemo-immunotherapy as per clinical practice
- Availability of follow-up
You will not qualify if you...
- Patients with other thoracic tumours non-NSCLC such as SCLC
- Stage other than IV or feasible for radical treatment upfront
- Treatment within clinical trials with combination regimens different from immunotherapy or chemo-immunotherapy
- Lost to follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Until disease progression or discontinuation
Participants receive first-line treatment with either immunotherapy alone or chemo-immunotherapy according to clinical practice.
Visits occur according to clinical practice during treatment
Duration - Up to 96 months
Participants are monitored for disease progression, lung toxicity, and long-term survival outcomes.
Visits as per clinical follow-up schedule
Trial Site Locations
Total: 1 location
1
Francesca Rita Ogliari
Milan, Italy, 20132
Actively Recruiting
Research Team
F
Francesca Rita Ogliari, MD
C
Clinical Trial Center OSR
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here